Drug developed for lung disease may slow biological aging in surprising ‘bonus’.
Rentosertib, an experimental drug discovered with AI, is being developed to treat idiopathic pulmonary fibrosis (IPF), a serious lung disease. Unexpectedly, the drug altered blood protein patterns, making patients appear an average of three to four years younger, with one case showing a six-year reduction in biological age. This suggests a potential "bonus" effect of slowing biological aging.
Time & source
- Published
- 09/09, 08:35 UTC+0
- Ingested
- 09/09, 18:00 UTC+0
- Source type
- Dev community
- Tier
- Community
- Source status
- Healthy
Tier is a per-source editorial setting, not a per-item score.
Rentosertib is an experimental drug, discovered with the help of artificial intelligence, that is being developed to treat idiopathic pulmonary fibrosis (IPF), a serious disease that causes scarring in the lungs.
In an unexpected outcome, the drug was found to change patterns of proteins in the blood in ways that made patients appear an average of three to four years younger, in one case up to six years.